ClinicalTrials.gov
public full text
Public Domain
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors#898373
- PRO1107 in Patients With Advanced Solid Tumors#852344
- A Study of DS5361b in Participants With Advanced Solid Tumors#847778
- Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies#906150
- A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors#1102496
Record · ID 912393
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive